Bone scan imaging to track heart amyloid in patients taking tafamidis
Tests bone scan imaging to follow heart amyloid in adults with transthyretin amyloidosis.
Plain-language title generated from the registry record
Registry title: Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy
Key facts
- Where
- Lille, FranceSee the site
Where in France
- Hôpital Privé Le BoisLille, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- GCS Ramsay Santé pour l'Enseignement et la Recherche
- Trial code
- NCT04849754
- Record updated
- 20 August 2026
- Original description
Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant reduction in mortality. The Perugini score is commonly used on planar bone scans to differentiate cardiac ATTR from other amyloidosis or normal patients but fails to evaluate amyloid burden and patient prognosis. Although semi-quantitative methods have been suggested to evaluate the amyloid burden, there a need for quantitative methods for longitudinal assessment of the disease.Read full original descriptionShow less
Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy for the Follow-up of Patients With Transthyretin Amyloidosis Treated With Tafamidis
Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant reduction in mortality. The Perugini score is commonly used on planar bone scans to differentiate cardiac ATTR from other amyloidosis or normal patients but fails to evaluate amyloid burden and patient prognosis. Although semi-quantitative methods have been suggested to evaluate the amyloid burden, there a need for quantitative methods for longitudinal assessment of the disease.
Inclusion: Patient, male or female, over 18 years of age; Patient diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy; Patient with signed consent.
Exclusion: Patients with systemic AL amyloidosis; Protected patient : major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision; Pregnant or breastfeeding woman.